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Abstract
Background: Endometrial cancer is the most common gynecological cancer. G-protein coupled receptor 64 (GPR64)
belongs to a family of adhesion GPCRs and plays an important role in male fertility. However, the function of GPR64
has not been studied in endometrial cancer. Our objective is to investigate the role of GPR64 in endometrial cancer.
Methods: We examined the levels of GPR64 in human endometrioid endometrial carcinoma by immunohistochemistry
analysis. To determine a tumor suppressor role of GPR64 in endometrial cancer, we used a siRNA loss of function
approach in human endometrial adenocarcinoma cell lines.
Results: GPR64 levels were remarkably lower in 10 of 21 (47.62%) of endometrial carcinoma samples compared to
control. Depletion of GPR64 by siRNA transfection revealed an increase of colony formation ability, cell proliferation, cell
migration, and invasion activity in Ishikawa and HEC1A cells. The expression of Connexin 43 (Cx43), a member of the
large family of gap junction proteins, was reduced through activation of AMP-activated protein kinase (AMPK) in
Ishikawa cells with GPR64-deficicy.
Conclusions: These results suggest that GPR64 plays an important tumor suppressor role in endometrial cancer.
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Background
Endometrial cancer is the most common gynecologic
malignancy, with an estimated 63,230 new cases in 2018
[1]. The most common type of endometrial cancer is
endometrioid adenocarcinoma, which originates from
endometrial epithelial cells [2]. The development of
endometrial hyperplasia, a proliferative process in the
epithelium, is the abnormal thickening of the lining of
the uterus due to an increase in the number of endomet-
rial glands. It is a critical risk factor for endometrioid
endometrial carcinoma [3]. Despite most cases being di-
agnosed in the early stages of endometrial cancer, a
subset of these patients have poor outcomes and a high
rate of recurrence and metastasis [4]. Recently, many
studies have focused on targeted molecular therapies for
controlling endometrial malignancies [5], however they
are still insufficient. Therefore, it is important to identify
molecular mechanisms involved in the development and
progression of endometrial cancer.
G-protein coupled receptor 64 (GPR64) is a member
of GPCR superfamily, which is crucial for male fertility
[6–8]. GPR64 was expressed in the proximal epididymis
and efferent ductule regions with are responsible for
spermatozoa maturation and rete testis fluid reabsorp-
tion [6–8]. In addition, expression of GPR64 was found
in fibroblast-like synovial cells in osteoarthritis [9]. The
level of GPR64 was higher in ewing sarcoma than other
mesenchymal neoplasms, and GPR64 induces placental
growth factor (PGF) and metalloproteinase (MMP1) ex-
pression [10]. Loss of GPR64 in ewing sarcoma cell line
leads to decreased PGF and MMP1 expression and reduced
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cellular growth with induced TRAIL dependent apoptosis
[10]. Also, GPR64 knock-down in an ewing sarcoma tumor
model in immune deficient mice, reduced metastasis and
invasiveness to the liver and lung [10]. GPR64 can activate
G-proteins GS/Gq when over-expressed in xenopus mela-
nophores [11]. Furthermore, GPR64 was identified as a
target gene of β-catenin/T-cell factor (TCF) in ovarian
endometrioid adenocarcinoma [12]. However, the role of
GPR64 in endometrial cancer is unknown.
Connexin 43 (Cx43) is a member of the large family of
gap junction proteins [13]. Gap junctions are intercellu-
lar plasma membrane proteins that provide for the ex-
change of ions and small molecules between adjacent
cells [14]. Some studies have indicated that the Cx43
channel was localized at the plasma membrane, but not
involved in Gap junction formation [15]. The Cx43
channel may regulate cell growth by transportation of
calcium ions or other ions between intracellular cyto-
plasm and the extracellular environment [15, 16]. Other
studies suggest that Cx43 can regulate cell growth
and death by direct interaction with regulated cell
cycle proteins including cyclin A, cyclin D1, p21, and
p27 [17, 18]. Dysregulation of gap junction intercellular
communication was to linked several human diseases such
as cancer, cardiac ischemia, Charcot-Marie-Tooth (CMT),
and Visceroatrial Heterotaxia Syndrom (VAH) [19, 20].
Cx43 is ubiquitously expressed in human tissues and con-
trols cell growth and differentiation via multiple mecha-
nisms. Attenuation of Cx43 is frequently observed in
cancers, resulting in loss of gap junctional intercellular
communication [21, 22]. Activation of Cx43 in cancer
cells derived from various tissue types has been shown to
result in restoration of normal cell growth and differenti-
ation [23]. Small interfering RNA (siRNA)-mediated
knockdown of Cx43 results in a more aggressive growth
of breast cancer cells [24]. Moreover, knock-out of Cx43
in mice results in increased susceptibility to chemically in-
duced lung adenomas [25]. There is an inverse correlation
between Cx43 expression and tumor grade in endometrial
cancer [26]. These observations suggest that Cx43 has a
tumor suppression function and is a potential target in
cancer therapy.
In this study, we examined the levels of GPR64 in
human endometrioid endometrial carcinoma. To investi-
gate the function of GPR64 in endometrial cancer, we
used GPR64 siRNA in human endometrial cancer cell
lines. Our results showed a new tumor suppressor role
for GPR64 in endometrial cancer.
Methods
Human endometrium samples
The human endometrioid endometrial carcinoma sam-
ples were obtained from The University of Texas MD
Anderson Cancer Center. The control endometrial
samples were obtained from hysterectomies (e.g., due to
leiomyoma or a uterus prolapse). All patients with endo-
metrial carcinoma underwent surgery. Twenty four con-
trols and 21 endometrial cancer samples (not paired)
were fixed in 10% buffered formalin prior to embedding
in paraffin wax.
Immunohistochemistry analysis
Immunohistochemistry analysis was performed as previ-
ously described [27]. Uterine cross sections from paraf-
fin-embedded tissue were cut into 6 μm sections,
mounted on saline-coated slides, deparaffinized and
rehydrated in a graded alcohol series. For antigen re-
trieval, heat-induced epitope retrieval was performed
using a pressure cooker with antigen unmasking solution
(H− 3300; Vector Laboratories, Burlingame, CA) and then
sections were pre-incubated with 10% normal rabbit
serum in phosphate-buffered saline (PBS; pH 7.5) then
incubated with anti-GPR64 (Sc-69,492; Santa Cruz Bio-
technology, Dallas, TX) antibody in PBS supplemented
with 10% normal rabbit serum overnight at 4 °C. The
next day, sections were washed with PBS and incubated
with secondary antibody conjugated to horseradish
peroxidase (Vector Laboratories, Burlingame, CA) for 1
h at room temperature. Immunoreactivity was detected
using diaminobenzidine (SK-4100; Vector Laboratories)
then counterstained with hematoxylin and coverslipped
with permount. Imunnostaining was analyzed using
microscopy software from NIS Elements, Inc. (Nikon
Instruments Inc., Melville, NY). A semi-quantitative
grading system (H-score) was used to compare the im-
munohistochemical staining intensities.
Cell culture and siRNA transfection
Human endometrial adenocarcinoma Ishikawa and
HEC1A cells were maintained in phenol red–free
DMEM/F12 medium (Gibco, Grand Island, NY) contain-
ing 0.1mM sodium pyruvate (Gibco), 10% fetal bovine
serum (FBS; Gibco), and 1% penicillin streptomycin (P/S;
Gibco). Cells were cultured in monolayer at 37 °C in 5%
CO2. GPR64 siRNA was obtained from Dharmacon (Lafa-
yette, CO), RNAi Technologies. Human GPR64 siRNA
was transfected using Lipofectamine 2000 reagent
(Invitrogen Crop., Carlsbad, CA) prior to in vitro culture.
Colony forming assay
After siRNA treatment, Ishikawa and HEC1A cells were
seeded into 6-well plates at a density of 2 × 102 cells per
2 ml cell culture medium and media was changed every
72 h for 14 days. Upon completion of culture, the plate
wells were washed with PBS, fixed with 4% paraformal-
dehyde and permeabilized with 100% methanol. Colonies
were stained with 1% crystal violet and images were
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captured via microscopy (Nikon Instruments Inc.) using
software from NIS Elements, Inc.
Cell proliferation assay
Cell proliferation was measured with a cell count kit-8
(Dojindo molecular technologies, Kumamoto, Japan)
assay according to the manufacturer’s instructions. After
siRNA treatment, 1 × 104 cells were seeded into 24-well
plate and cell proliferation was documented every 24 h
for 10 days.
Wound healing assay
Cell migration was measured by a wound healing assay.
1 × 105 Ishikawa and HEC1A cells were seeded into 12-
well plate and human GPR64 siRNA was transfected into
cells. After siRNA treatment, cells were incubated for 24
h. After 24 h, a pipette tip was used to create a scratch
through the cell monolayer and cells were maintained in
growth medium at 37 °C in 5% CO2. Cell migration was
measured after 48 h, via inverted microscopy (Nikon In-
struments Inc.) and distance was determined by Image J
software (National Institute of Health, USA). Cell migra-
tion rate was converted to a percentage that measured
the area compared to directly after the scratch.
Invasion assay
For the transwell invasion assay, Ishikawa and HEC1A
cells treated with siRNA were plated in the top chamber
of a matrigel-coated membrane (24-well insert; pore size,
8 μm; BD Biosciences) at a density of 2.5 × 105 per 200 μl
serum-free culture medium and culture medium with
10% serum was used as a chemoattractant in the lower
chamber. The cells were incubated at 37 °C in 5% CO2
for 48 h and cells that did not invade through the pore
were removed by a cotton swab. Cells on the lower
surface of the membrane were fixed with 4% paraformal-
dehyde and permeabilized with 100% methanol. Cells
were stained with 1% crystal violet, and images were
captured via fluorescent microscopy (Nikon Instruments
Inc.) using software from NIS Elements, Inc.
Annexin V/PI assay
Apoptotosis was measured with a FITC Annexin V
Apoptosis Detection Kit I (BD Pharmigen, San Diego,
CA) assay according to the manufacturer’s instructions.
After siRNA treatment, 1 × 106 cells were washed twice
with cold PBS and resuspend cells in 1X binding buffer.
100 ul of the solution with 1 × 105 cells was transfered to
a 5 ml culture tube and added 5 ul of FITC Annexin V
and 5 ul PI. The cells were gently vortexed and incu-
bated at room temperature in the dark. After 15 min,
400 ul of 1X binding buffer was added to culture tube
and analyzed by Flow cytometry (FACScalibur; Becton
Dickinson, San Jose, CA). The data was analyzed using
BD cell/Quest Pro software (Becton Dickinson).
RNA isolation and quantitative RT-qPCR
Total RNA was isolated using the RNeasy total RNA iso-
lation kit (Qiagen, Valencia, CA) according to the manu-
facturer’s instructions. As a template for quantitative
RT-qPCR, cDNAs were synthesized using quantitative
PCR random hexamers and MMLV Reverse Transcript-
ase (Invitrogen Crop.). The expression of Cx43 was
quantified by real-time PCR using a CFX96 Real-time
Detection System (Bio-Rad Laboratories, Hercules, CA)
and iQ™ SYBR Green Supermix (Bio-Rad Laboratories).
RPL7 expression was included in each treatment group
for normalization. The sequences of the primers used for
GPR64 were 5′-CTGCAGGATCCCATTGTCTG-3′ and
5′-TGAAAGGGGTTGAATCTCCC-3′, for Cx43 were
5′-ATGAGCAGTCTGCCTTTCGT-3′ and 5′-TCTGCT




Western blot analyses were performed as described
previously [27]. Briefly, twenty five micrograms of protein
lysates were electrophoresed via SDS-PAGE and trans-
ferred onto polyvinylidene difluoride membrane (Milli-
pore Corp., Bedford, MA). The membrane was blocked
with Casein (0.5% v/v) prior to exposure to anti-GPR64
(sc-69,492 Santa Cruz Biotechnology), anti-phospho-
AMPK (Thr 172, #5235; Cell Signaling, Danvers, MA),
anti-AMPK (#2532, Cell Signaling), anti-Cx43 (#3512, Cell
Signaling), and anti-β-actin (SC-47778; Santa Cruz
Biotechnology) antibodies. Immunoreactivity was visual-
ized by incubation with a horseradish peroxidase-linked
secondary antibody followed by exposure to electro-
chemiluminescence reagents (ECL) according to the
manufacturer’s instructions (GE Healthcare Biosci-
ences, Piscataway, NJ).
Immunofluorescence
Immunofluorescence was performed as described previ-
ously [27]. Ishikawa cells were grown on glass coverslips
and transfected with GPR64 siRNA. Upon completion of
growth, coverslips were washed with PBS, fixed with 4%
paraformaldehyde and permeabilized with 0.1% of Triton
X-100 (Sigma-Aldrich, St. Louis, MO). After further
washing, Ishikawa cells were exposed to anti-GPR64 (sc-
69,492; Santa Cruz Biotechnology) and anti-Cx43
(#3512; Cell Signaling) antibodes overnight at 4 °C and
secondary antibodes for 2 h at room temperature.
Washed coverslips were then mounted onto microscope
slides with a DAPI-impregnated mounting media (Vec-
tor Laboratories) to enable nuclear visualization, and
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images were captured via a Zeiss LSM700 confocal micro-
scope (Carl Zeiss microImaging GmBH, Jena, Germany)
using ZEN 2009 software (Carl Zeiss microImaging).
Statistical analysis
Cell experiments were measured in triplicate and aver-
aged to achieve a single value for each combination of
treatment, time point, and cell line. Statistical analyses
were performed using one-way ANOVA analysis,
Tukey’s post hoc multiple range test or Student’s t-tests
using the Instat package from GraphPad (San Diego,
CA). p < 0.05 was considered statistically significant.
Results
The levels of GPR64 are altered in a subset of
endometrial cancer
To determine the levels of GPR64 in endometrial cancer,
we performed immunohistochemical analysis using tis-
sue from 24 controls and 21 endometrioid endometrial
carcinoma samples. In control endometrium, GPR64
proteins were strongly detected in the nucleus, cytosol
and apical membranes of stromal and epithelial cells of
endometrium from the proliferative phase and secretory
phases in women and the levels of GPR64 proteins were
not significantly changed during the menstrual cycle
(Fig. 1a). Interestingly, the levels of GPR64 were signifi-
cantly lower in 47.62% (10/21) of endometrial cancer
tissue compared with controls (p < 0.001). However,
levels of GRP64 were unchanged in 52.38% (11/21) of
endometrial cancer samples (Fig. 1b; p = 0.0841). Epi-
didymal tissue was included for the immunohistochem-
istry of GPR64 as a positive control [28, 29]. The
expression of GPR64 was detected in apical membranes
as well as in some nuclei of epididymal duct epithelial
cells (Additional file 1: Figure S1). These results suggest
that GPR64 may play a tumor suppressor role in certain
cases of endometrial cancer.
Attenuation of GPR64 increases colony forming ability
and cell proliferation
The continual unregulated proliferation of cells is essen-
tial to cancer development [30, 31]. To characterize the
proliferative role of GPR64 in endometrial cancer, we
performed a colony forming assay and a cell prolifera-
tion assay in Ishikawa and HEC1A cells transfected with
GPR64 siRNA. First, we confirmed the decrease of
GPR64 mRNA and protein levels by GPR64 siRNA
transfection compared to non-targeting pool siRNA by
RT-qPCR and western blot analysis, respectively (Fig. 2 a
and b). The colony formation assay enables us to deter-
mine the survival and proliferation of cells [32]. Colony
formation ability was significantly increased in Ishikawa
and HEC1A cells transfected with GPR64 siRNA
compared to control (Fig. 2 c and d). Furthermore, the
A
B
Fig. 1 Levels of GPR64 in human endometrial cancer. a Representative immunohistochemistry andsemiquantitative analysis for GPR64 expression
in control endometrium from women in proliferative, early, and mid-secretory phases. b Representative immunohistochemistry and
semiquantitative analysis for GPR64 expression in endometrial cancer tissues. The semiquantitative analysis of immunohistochemistry analysis was
calculated by H-score among 24 control endometrium and 21 endometrial cancer tissues. High level of GPR64 was observed in 100% control
endometrium (6/6) and 52.38% endometrial cancer (11/21), and low level was observed in 47.62% endometrial cancer (10/21). ***, p < 0.001
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proliferation levels of Ishikawa cells were significantly
increased by GPR64 siRNA transfection after 4 days
(Fig. 2e). The proliferation of HEC1A cells was also
significantly increased by GPR64 siRNA transfection
after 3 days (Fig. 2f). Next, we examined whether
GPR64 regulates cell apoptosis using an Annexin V/
PI assay. The ratio of apoptotic cells was not different
between GPR64 siRNA-transfected cells and non-tar-
geting pool siRNA transfected cells of Ishikawa and
HEC1A cells (Additional file 1: Figure S2). These re-
sults suggest that GPR64 suppresses epithelial prolif-
eration of endometrial cancer cells.
Attenuation of GPR64 increases cell migration and
invasion
We examined the effect of GPR64 attenuation in cell mi-
gration and invasion. Our wound healing assay revealed
that reduction of GPR64 by RNA interference signifi-
cantly increased the migration ability of Ishikawa and
HEC1A cells (Fig. 3). The GPR64-deficient Ishikawa cells
recovered the wound over 61% after 48 h, while control
cells healed less than 44% of wound distance (Fig. 3a).
The HEC1A cells with GPR64 knockdown recovered the
wound over 71% but the control cells healed only less
than 59% of wound distance (Fig. 3b).
Attenuation of GPR64 exhibited a significantly higher
infiltration rate in the transwell invasion assay of
Ishikawa and HEC1A cells compared to siRNA con-
trols. Invasion ability of GPR64-deficient Ishikawa cells
was increased by more than three-times compared to
control cells (Fig. 4a), and invasion ability of GPR64
knockdown HEC1A cells was increased by more than
two-times (Fig. 4b).
Attenuation of GPR64 reduces the expression of
Connexin 43 trough activation of AMPK
Activation of AMP-activated protein kinase (AMPK)
plays a critical role in induction of EMT in multiple
cancer cell types [37]. To determine whether AMPK ac-
tivity is regulated by depletion of GPR64, we examined
phosphorylation level of AMPK (Thr 172) in Ishikawa
cells transfected with GPR64 siRNA. The levels of pho-
phorylated AMPK were increased by GPR64 knock-




Fig. 2 Effect of GPR64 loss on cell growth in human endometrial cancer cells. a and b The expression of GPR64 mRNA and protein in Ishikawa
(a) and HEC1A (b) cells transfected with non-targeting pool (NT) siRNA or GPR64 siRNA was examined by RT-qPCR and Western blot analysis,
respectively. c and d Colony formation assay of Ishikawa (c) and HEC1A (d) cells transfected with NT siRNA or GPR64 siRNA. Samples from each
treatment were transferred to flat-bottomed 24-well plates and incubated. Cells were fixed and stained with crystal violet. The average colony
formation number was quantified with crystal violet stained cells. e and f Cell proliferation assay of Ishikawa (e) and HEC1A (f) cells transfected
with NT siRNA or GPR64 siRNA. The results represent the mean ± SEM. *, p < 0.05; **, p < 0.01; and ***, p < 0.001
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were not different between control and GPR64-deficient
cells (Fig. 5a).
Connexin proteins are frequently dysregulated in tu-
mors, resulting in loss of gap junctional intercellular
communication [21, 22]. Many tumors with decreased
Cx43 expression exhibited dysfunctional gap junctional
intercellular communication [19, 38, 39]. The expression
and function of Cx43 have been correlated with carcino-
genesis in endometrial cancer [26, 40]. Therefore, we
examined the levels of Cx43 proteins and mRNA in Ishi-
kawa cells with GPR64 knockdown using RT-qPCR and
Western Blot analysis. Depletion of GPR64 significantly
reduced the levels of Cx43 proteins on day 1 and day 6
compared with non-targeting pool siRNA by Western
blot analysis (Fig. 5 a and b). The expression of Cx43
mRNA was significantly reduced in the Ishikawa cells
treated with GPR64 siRNA on day 3 and day 6 compared
with non-targeting pool siRNA (Fig. 5c).
Next, we performed double immunofluorescence for
GPR64 and Cx43 after GPR64 knock-down (Fig. 6).
GPR64 is colocalized with Cx43 in Ishikawa cells.
However, the expression of Cx43 protein was remark-
ably reduced in GPR64-deficient cells by GPR64 siRNA
compared to non-targeting pool siRNA.
Discussion
G protein-coupled receptors (GPCRs) are transmem-
brane receptors and play important roles in multiple
biological processes. Aberrant expression of these recep-
tors has been linked to cancer development and progres-
sion [43–45]. However, the molecular function of
GPCRs is not known in endometrial cancer. The present
study shows that the expression of GPR64 was distinctly
lower in a subset of endometrioid endometrial carcin-
oma. These results suggest a tumor suppressor role of
GPR64 in endometrial cancer.
Recently, Richter et al. identified that GPR64 is specif-
ically overexpressed in Ewing sarcoma (ES) but is also
up-regulated in prostate, kidney, and lung carcinoma
[10]. This study identified that suppression of GPR64 in
ES by siRNA, led to impaired colony formation, cell
growth, and metastasis in Rag2(−/−) γC(−/−) mice. Moreover,
A
B
Fig. 3 Ability of cell migration associated with GPR64 expression in endometrial cancer. The wound healing assay was performed in Ishikawa (a)
and HEC1A (b) cells transfected with NT siRNA or GPR64 siRNA. After scratch, cells were incubated for 48 h to determine the cell migration ability.
Representative result of wound healing assay and quantification of cell migration by wound healing assay during in vitro culture. The results
represent the mean ± SEM. *, p < 0.05
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suppression of GPR64 induced TRAIL mediated apoptosis
and reduced PGF and MMP1 expression [10]. GPR64 is
also involved in cell adhesion and migration through acti-
vation of serum response element (SRE) and nuclear factor
kappa-light-chain-enhancer of activated B cells (NFκB) and
its knockdown by siRNA in the highly motile breast cancer
cell lines results in a reduction in cell adhesion and migra-
tion [46]. However, our results showed that depletion of
GPR64 increases the cell proliferation, migration, and inva-
sion of endometrial cancer cells. These results suggest the
role of GPR64 as a tumor suppressor in endometrial can-
cer. It remains possible that GPR64 plays dual functions in
different cancer conditions depending on the spatial and
temporal distribution and abundance of different GPR64
downstream targets and factors that regulate GPR64. Our
results suggest a new role of GPR64 as a tumor suppressor
in endometrial cancer, but further studies are needed to
provide a conclusive answer.
Unfortunately, we could not characterize the subtype
of endometrial cancers where GPR64 could be a tumor
A
B
Fig. 4 An increase of cell invasion by GPR64 loss in endometrial cancer cells. Representative result of transwell invasion assays of Ishikawa (a) and
HEC1A (b) cells transfected with NT siRNA or GPR64 siRNA. Quantification of invasion through matrigel and transwell membrane in Ishikawa and
HEC1A cells with or without GPR64 siRNA treatment. The results represent the mean ± SEM. **, p < 0.01
A B C
Fig. 5 The reduction of Cx43 levels by GPR64 loss through AMPK activation in Ishikawa cells. a The Western blot analysis of phospho-AMPKThr172,
Total AMPK, and Cx43 proteins in Ishikawa cells transfected with NT siRNA or GPR64 siRNA on day 1 and day 6. Actin was used as sample-loading
control. b Quantification of western blot analysis of Cx43. c The expression of Cx43 gene during in vitro culture after GPR64 siRNA transfection.
Cx43 was significantly decreased on day 3 and day 6 in cells transfected with GPR64 siRNA. The results represent the mean ± SEM. *, p < 0.05; and
**, p < 0.01
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suppressor. The levels of GPR64 were not correlated
with grade or stage of endometrial endometrioid adeno-
carcinoma which is the most frequently occurring endo-
metrial cancer cell type [47]. Cancer classification in the
clinic is primarily based on histological analysis in the
proper clinical context. Although highly informative,
histopathology can be hampered by limitation in its
ability to distinguish subtypes of cancers and molecular
signatures. Although we could not characterize the sub-
type of endometrial tumors based on GPR64 levels in
this study, composite molecular profiling of tumor speci-
mens is increasingly becoming recognized as an adjunct
to traditional histopathology. Therefore, the molecular
characterization of tumor types using GPR64 expression
may help to identify additional objective tools to en-
hance the classification of endometrial cancer. However,
there is a need to investigate a tumor suppressor role of
GPR64 in specific subtypes of endometrial cancer.
Several adhesion GPCRs have been shown to be
involved in cell adhesion and migration, hereby influen-
cing tumor progression [46]. GPR26 is a potent regulator
of energy homeostasis through controlling hypothalamic
AMP-activated protein kinase (AMPK) activation [48].
AMPK inhibits Cx43 expression in bladder smooth
muscle cells [36]. While total AMPK levels were not
different between control and GPR64-deficient cells, the
levels of phophorylated AMPK were increased by GPR64
knock-down compared to control. AMPK is associated
with cancer development as an important mediator in
maintaining cellular energy homeostasis [33, 34], and its
activity is increased by extracellular changes such as de-
pletion of ATP, low glucose, and changes of NADPH
levels [35]. Additionally, AMPK inhibits Cx43 expression
in bladder smooth muscle cells [36]. Cx43 expression has
been associated with a wide variety of cancers, including
liver tumor, colon cancer, breast cancer, ovarian carcin-
oma, and endometrial cancer [41]. Its role in controlling
cell motility and polarity contributes to cancer develop-
ment and metastasis. Especially, Cx43 decreased with poor
differentiation of endometrial cancer [26], and Cx43 is
considered to be weakened in progression of carcinogen-
esis [40, 42]. Thus, our results suggest that GPR64 is a
tumor suppressor in endometrial cancer by regulating
Cx43 expression through regulation of AMPK activity.
Conclusions
We found an attenuation of GPR64 expression in a
subset of endometrial cancer. We demonstrated that
depletion of GPR64 induced tumorigenic potentials by
promoting cell proliferation, migration, and invasion in
endometrial cancer cells. GPR64 regulates the expression
of Cx43 and AMPK activity in endometrial cancer cells.
These results suggest that GPR64 acts as a tumor sup-
pressor in endometrial cancer.
Additional file
Additional file 1: Figure S1. Expression of GPR64 in mouse epididymis.
The immunohistochemistry for GPR64 was performed in mouse
epididymis as a positive control. Immunohistochemical staining of mouse
epididymis shows membranous and nuclear positivity in epididymal duct
epithelial cells. Figure S2. Effect of GPR64 on cell apoptosis in human
endometrial cancer cells. Annexin V/PI assay were performed in Ishikawa
(A) and HEC1A (B) cells transfected with with non-targeting pool (NT)
siRNA or GPR64 siRNA to determine the effect of GPR64 on cell
apoptosis. The apoptotic cells were analyzed by Flow cytometry. No
difference was found between there were no significant difference
between NT siRNA and GPR64 siRNA treatments. (PPTX 330 kb)
Fig. 6 The colocalization of GPR64 with Cx43 in Ishikawa cells. The
colocalization of GPR64 (red) and Cx43 (green) were analyzed in
Ishikawa cells transfected with NT siRNA or GPR64 siRNA by
fluorescence microscopy. GPR64 overlaps with Cx43, but its
colocalization was affected by reduction of GPR64. Nuclei were
counterstained with DAPI staining
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